Impaired endothelium-dependent forearm vasodilation in idiopathic dilated cardiomyopathy is related to severe left ventricular dysfunction and elevated serum tumor necrosis factor levels

被引:5
作者
Sitges, M [1 ]
Roig, E [1 ]
Morales, M [1 ]
Azqueta, M [1 ]
Villa, FP [1 ]
Paré, C [1 ]
Orús, J [1 ]
Heras, M [1 ]
Sanz, G [1 ]
机构
[1] Univ Barcelona, IDIBAPS, Hosp Clin, Inst Malalties Cardiovasc, Barcelona, Spain
来源
REVISTA ESPANOLA DE CARDIOLOGIA | 2005年 / 58卷 / 05期
关键词
dilated cardiomyopathy; endothelial dysfunction; tumor necrosis factor;
D O I
10.1157/13074841
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives. Endothelial dysfunction has been found in patients with idiopathic dilated cardiomyopathy (IDC), but its mechanism remains unknown. Our aim was to investigate whether forearm endothelium-dependent vasoreactivity correlates with cardiac disease severity or neurohormonal activation. Patients and method. We studied 23 patients with IDC and 10 healthy sex- and age-matched controls using brachial artery ultrasound to assess flow-mediated dilation (FMD) and nitroglycerin-induced vasodilation (NIV). In the IDC group, we determined plasma neurohormone and cytokine levels at the same time. Results. FMD was significantly less in the IDC group compared with the control group [-0.06 (2.8)% vs 4.4 (4.6)%, respectively; P<.01), whereas NIV was similar in both groups [15.0 (6.4)% vs 14.0 (7.4)%, respectively; P=NS]. FMD was significantly less in patients with poorer left ventricular (LV) function and more severe LV dilatation, and in those with a higher tumor necrosis factor-alpha (TNF-alpha) level. NIV was similar in all patient subgroups. There was a significant inverse correlation between the TNF-alpha plasma level and FMD (r=-0.75; P<.01). No correlation was found between the plasma levels of other neurohormones and FMD. Conclusions. FMD, but not NIV, was impaired in patients with IDC compared with control subjects. In patients, there were significant associations between FMD impairment and the severity of LV dilatation, the severity of LV systolic dysfunction, and the plasma TNF-alpha level.
引用
收藏
页码:477 / 483
页数:7
相关论文
共 30 条
  • [1] Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure
    Adamopoulos, S
    Parissis, J
    Karatzas, D
    Kroupis, C
    Georgiadis, M
    Karavolias, G
    Paraskevaidis, J
    Koniavitou, K
    Coats, AJS
    Kremastinos, DT
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (04) : 653 - 663
  • [2] Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure
    Anker, SD
    Volterrani, M
    Egerer, KR
    Felton, CV
    Kox, WJ
    Poole-Wilson, PA
    Coats, AJS
    [J]. QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1998, 91 (03): : 199 - 203
  • [3] [Anonymous], 1994, CYTOKINES CELLULAR M
  • [4] Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
    Bozkurt, B
    Torre-Amione, G
    Warren, MS
    Whitmore, J
    Soran, OZ
    Feldman, AM
    Mann, DL
    [J]. CIRCULATION, 2001, 103 (08) : 1044 - 1047
  • [5] Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α
    Bryant, D
    Becker, L
    Richardson, J
    Shelton, J
    Franco, F
    Peshock, R
    Thompson, M
    Giroir, B
    [J]. CIRCULATION, 1998, 97 (14) : 1375 - 1381
  • [6] Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium?
    Ceconi, C
    Curello, S
    Bachetti, T
    Corti, A
    Ferrari, R
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 1998, 41 (01) : 25 - 30
  • [7] Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
    Chung, ES
    Packer, M
    Lo, KH
    Fasanmade, AA
    Willerson, JT
    [J]. CIRCULATION, 2003, 107 (25) : 3133 - 3140
  • [8] Tumour necrosis factor α gene polymorphism:: a predisposing factor to non-ischaemic myocardial dysfunction?
    Densem, CG
    Hutchinson, IV
    Yonan, N
    Brooks, NH
    [J]. HEART, 2002, 87 (02) : 153 - 155
  • [9] Endothelium as a therapeutic target in heart failure
    Drexler, H
    [J]. CIRCULATION, 1998, 98 (24) : 2652 - 2655
  • [10] DREXLER H, 1995, AM J CARDIOL, V76, P13